Latest News

The perception that the situation regarding funded access to medicines in Australia is viewed as favourable unquestionably reveals more about the reality in New Zealand. If denial is your daily expectation, anything better looks good.

Australia’s leading pharmacy and medical bodies have called for an urgent reset of medicinal cannabis policy, warning that rapid growth in prescribing and dispensing has outpaced safeguards and is putting patients at risk.

“By working together, we hope to accelerate the discovery and clinical development of an important novel treatment. I am looking forward to working with a team that puts such an emphasis on open communication, long-term partnership, and shared success,” Kathryn Evans, General Manager, argenx Australia, said.

The former head of AZ in Australia and New Zealand, and Medicines Australia chair, has been appointed to chair a local company most well-known for its 'green whistle' emergency pain treatment.

Power rarely yields voluntarily. It is far more likely to consolidate. Those who have it, keep it. Those who lack it and operate within the same framework learn to survive. The result is a self-reinforcing loop in which process becomes the shield and complexity the excuse. Sound familiar?

PYC Therapeutics (ASX:PYC) is advancing its Phelan-McDermid syndrome (PMS) program toward first-in-human studies, reporting non-human primate results that, along with earlier patient-derived neuron data, support progression to the clinic.

Medical Developments International (ASX:MVP) used its 2025 AGM to draw a clear line under its rebuild and set out a confident growth agenda.

Artrya (ASX:AYA) has taken an essential step toward US clearance of its Salix Coronary Flow module, confirming a successful Q-Submission meeting with the Food and Drug Administration that provided clear guidance for a 510(k) application.

Adherium (ASX:ADR) has launched an Early Exercise Incentive Offer that rewards eligible optionholders who subscribed under the company’s placement and accelerated non-renounceable entitlement offer.

Has Senate Estimates become a polite, time-sliced ritual that enables waffle, obfuscation, and endless 'taken on notice' responses? The exchanges exposed review processes designed to protect institutional power, shift blame, and deepen complexity. Few appear willing to say the quiet part out loud.

David Seymour, Deputy Prime Minister and Associate Health Minister responsible for Pharmac, will give the opening address at this week's Valuing Life – Medicines Access Summit in Wellington.

Pharmaceutical pricing and access are like water in that they seek the fastest path. Countries like Australia and New Zealand have consistently dammed that path over many decades, primarily to divert the water, slow it down, and give themselves time to secure the lowest prices. Is the US on the verge of shutting off the water?